Document Detail


B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures.
MedLine Citation:
PMID:  17161055     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are frequently used in diagnosing and monitoring patients with heart failure. Recent studies have demonstrated that concentrations of these peptides are decreased in obese patients, but whether lower natriuretic peptide concentrations are really due to different hemodynamics is unknown. The relationship between these markers and left ventricular end diastolic pressure (LVEDP) in obesity has not been elucidated. METHODS: We examined patients undergoing cardiac catheterization who had creatinine of < 2.0, no evidence of myocardial infarction or pulmonary embolism, and no cardiac transplant. Body mass index and LVEDP were determined, and BNP and NT-proBNP obtained at the start of each case. Obesity was defined as body mass index of > or = 30 kg/m2. RESULTS: Of 203 patients enrolled, 101 were obese. The groups were similar in respect to race, creatinine, cholesterol, and history of dyslipidemia and cardiomyopathy. The obese patients tended to be younger, were more likely to have diabetes and hypertension, and were less likely to have coronary artery disease. The obese patients had higher LVEDP but reduced BNP and NT-pro-BNP. The relationship between the natriuretic peptides and LVEDP was poor, with r values of < 0.1. CONCLUSIONS: Obese patients have reduced concentrations of BNP and NT-proBNP compared to nonobese patients despite having elevated LVEDP. This suggests that factors other than cardiac status impact on BNP and NT-proBNP concentrations. The poor relationship between natriuretic peptide concentrations and LVEDP also suggests that these concentrations should not be considered surrogates for cardiac filling pressures or volumes.
Authors:
Jennifer A Taylor; Robert H Christenson; Krishnamurti Rao; Melinda Jorge; Stephen S Gottlieb
Related Documents :
17161055 - B-type natriuretic peptide and n-terminal pro b-type natriuretic peptide are depressed ...
17653025 - Emerging cardiac markers in coronary disease: role of brain natriuretic peptide and oth...
9820995 - Two-year time course and significance of neurohumoral activation in the survival and ve...
16741745 - Postmortem pericardial natriuretic peptides as markers of cardiac function in medico-le...
23188125 - Intramyocardial delivery of hmgb1 by a novel thermosensitive hydrogel attenuates cardia...
2554155 - Ventricular and atrial electrophysiological effects of a ic antiarrhythmic drug, cibenz...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American heart journal     Volume:  152     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2006-12-12     Completed Date:  2007-01-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1071-6     Citation Subset:  AIM; IM    
Affiliation:
The University of Maryland School of Medicine and the Baltimore Veteran's Affairs Medical Center, Baltimore, MD, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Blood Pressure*
Female
Humans
Linear Models
Male
Middle Aged
Natriuretic Peptide, Brain / blood*
Obesity / blood,  physiopathology*
Osmolar Concentration
Peptide Fragments / blood*
Regression Analysis
Ventricular Function, Left*
Chemical
Reg. No./Substance:
0/Peptide Fragments; 0/pro-brain natriuretic peptide (1-76); 114471-18-0/Natriuretic Peptide, Brain

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evidence-based cardiovascular therapies and achievement of therapeutic goals in diabetic patients wi...
Next Document:  Total cholesterol levels and mortality risk in nonischemic systolic heart failure.